When was ViaCyte founded?

ViaCyte was founded in 1999 and raised its 1st funding round 8 years after it was founded.

Where is ViaCyte located?

ViaCyte is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does ViaCyte have?

As of Apr 30, 2026, the latest employee count at ViaCyte is 15.

Is ViaCyte a funded company?

ViaCyte is a funded company, having raised a total of $389M across 18 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Jul 16, 2007.

When was the latest funding round of ViaCyte?

ViaCyte's latest funding was a $***** Series D round on Jun 09, 2021, with participation from 8 investors.

Where does ViaCyte rank among its competitors?

ViaCyte ranks 60th amongst 325 active competitors, of which 107 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Lexicon Pharmaceuticals, which secured $55.7M in Feb, 2026.

Who are the top competitors of ViaCyte?

ViaCyte's top competitors include Sana Biotechnology, MannKind Corp and Corcept. Among them, Lexicon Pharmaceuticals secured the most recent funding round in February, 2026.

ViaCyte - 2026 Company Profile, Funding & Competitors

Company Details

ViaCyte focused on developing a novel cell therapy for the treatment of diabetes. ViaCyte’s lead product candidate, the VC-01 combination product, is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. VC-01 is being developed as a potential long-term diabetes treatment without immune suppression and without risk of hypoglycemia or other diabetes-related complications.

Website: viacyte.com
Social
Email ID: *****@viacyte.com, *****@viacyte.com
Phone Number: +1 **********
Registered Address: San Diego, California

Key Metrics

Founded Year

1999

Location

San Diego, United States

Stage

Acquired

Total Funding

$389M in 18 rounds

Latest Funding Round

Series D, Jun 09, 2021, $*****

Investors

Bain Capital Life Sciences & 22 more

Ranked

60^th among 325 active competitors

Employee Count

15 as on Apr 30, 2026

Similar Companies

Sana Biotechnology & 422 more

Exit Details

Acquired by Vertex Pharmaceuticals (Jul 11, 2022)

View ViaCyte's full profile

ViaCyte is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Viacyte, Inc. CIN: 330884172 , United States, Active		-	105 (As on Dec 31, 2022)	-

ViaCyte got acquired by Vertex Pharmaceuticals on Jul 11, 2022 at an acquisition amount of $*****.

Click here to take a look at ViaCyte's acquisition in detail

ViaCyte has raised a total funding of $389M over 18 rounds. Its first funding round was on Jul 16, 2007. Its latest funding round was a Series D round on Jun 09, 2021 for $*****. 8 investors participated in its latest round. ViaCyte has 23 institutional investors.

Here is the list of recent funding rounds of ViaCyte:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 09, 2021	4959066	Series D	9220115	7725256	8273181	6515217
Apr 22, 2021	4240790	Series D	5995144	1044283	2034634	5011721
Apr 02, 2020	4123904	Series D	4872772	1565882	Sanderling Ventures & 2 more	9691803

Access funding benchmarks and valuations. Sign up today!

View details of ViaCyte's funding rounds and investors

ViaCyte's employee count trend

ViaCyte has 15 employees as of Apr 26. Here is ViaCyte's employee count trend over the years:

Uncover ViaCyte's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ViaCyte include Sana Biotechnology, MannKind Corp and Corcept. Here is the list of Top 10 competitors of ViaCyte, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Omega Funds & 17 others	75/100
2nd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	72/100
3rd	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Cornerstone Capital, Longitude Capital & 6 others	69/100
4th	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
5th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	New Enterprise Associates, Bay City Capital ... & 3 others	68/100
6th	89bio 2018, San Francisco (United States), Acquired	Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders	$60M	Orbimed, Longitude Capital & 3 others	67/100
7th	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, CAM Capital & 8 others	67/100
8th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Third Rock Ventures, Pfizer Venture Investments ... & 8 others	66/100
9th	Zucara Therapeutics 2015, Vancouver (Canada), Series B	Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes	$50.8M	TIAP, Cdrd.ca & 14 others	66/100
10th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Khosla Ventures, 8VC & 7 others	65/100
60th	ViaCyte 1999, San Diego (United States), Acquired	Developer of cell therapy for the treatment of diabetes	$389M	Bain Capital Life Sciences, CIRM & 21 others	48/100